Ansun Biopharma Secures $80 Million Series B Financing to Advance DAS181, a Breakthrough Therapy-Designated Drug for PIV-Induced Lower Respiratory Tract Infections

VCBeat (WeChat ID: vcbeat) has learned that Ansun Biopharma, dedicated to developing first-in-class innovative biologics addressing the most urgent and unmet clinical needs in the field of respiratory infections, recently announced the completion of an $80 million Series B financing round. The round was led by Haisong Capital, with participation from the Greater Bay Area Common Home Development Fund, Jiachen Capital, KIP, and existing investors Yuanming Capital, Lilly Asia Ventures, Matrix Partners China, Bencao Capital, and Jefferies Capital. China Renaissance served as the exclusive financial advisor for this financing.

Ansun Biopharma is a clinical-stage biopharmaceutical company. Its lead product in clinical development, DAS181, is a first-in-class recombinant sialidase protein that effectively cleaves sialic acids on the surface of human respiratory epithelial cells, thereby hindering viral entry into host cells and blocking viral infection. As a host-targeted therapy, DAS181 holds promise for treating various respiratory viral infections that utilize the same mechanism of infection. The U.S. FDA has granted DAS181 Fast Track designation and Breakthrough Therapy designation for the treatment of lower respiratory tract infections caused by parainfluenza virus (PIV) in immunocompromised patients.

The funds raised in this round will be primarily used for the ongoing Phase III global multicenter pivotal clinical trials of this product, as well as for expanding into other indications.

Dr. Nancy Tang, Chairman and Chief Executive Officer of Ansun Biopharma, stated, “We are delighted to have the support and recognition of both new and existing investors. This financing will continue to support the rapid advancement of our product pipeline.”

Mr. Chen Liguang, Founder, CEO, and Managing Partner of Haisong Capital, stated, “With its novel and unique antiviral mechanism, Ansun has developed DAS181, a first-in-class biologic addressing the significant unmet clinical need for respiratory tract infections caused by parainfluenza viruses. Furthermore, DAS181 has the potential to become a best-in-class therapy in the equally substantial market for influenza virus infections. As a successful investor and serial entrepreneur, Dr. Nancy Tang has led an elite team to efficiently secure FDA Fast Track designation and Breakthrough Therapy designation for DAS181, while continuing to advance successfully toward Phase III clinical trials. As a specialized investment institution focused on global leading innovative biopharmaceutical companies and an existing shareholder of Ansun, Haisong Capital will continue to leverage our industry resources to support the company’s ongoing innovation, helping it become a benchmark enterprise in the global innovative biopharmaceutical sector.”

Yu Rui, Managing Director at China Renaissance, stated, “We are honored to have assisted the company in completing this round of financing. Ansun Biopharma boasts a lean, efficient, and experienced management team. We believe that the success of this financing round will accelerate the clinical development of its leading product candidate, DAS181, thereby facilitating an earlier market launch.”